Acute Heart Failure (AHF) Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (B-Blockers, Calcium Channel Blockers, Cardiac Glycosides, Diuretics, Morphine, Vasodilators/Nitrates, Others), By Application (Hospital, Clinic, Home Care) Regional Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

ACUTE HEART FAILURE (AHF) THERAPEUTICS MARKET OVERVIEW

The global Acute Heart Failure (AHF) Therapeutics Market size was USD 0.53 billion in 2024 and is expected to reach USD 4.53 billion by 2033, growing at a compound annual growth rate (CAGR) of about 26.8% during forecast period.

The global COVID-19 pandemic has been unprecedented and staggering, with the global acute heart failure (AHF) therapeutics Market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

Bluetooth-enabled cardiac devices are a recent discovery that can measure a variety of parameters and send the data back to medical specialists for remote patient therapy. A considerable increase in healthcare spending in developing countries and the prevalence of obesity worldwide will further help the industry's prediction. Treatment for congestive heart failure will significantly grow in the next years since obesity is linked to an enlarged left ventricle.

COVID-19 IMPACT

Imposed Restrictions in the Economy Resulted in Decline in the Market 

The COVID-19 problem has had an impact on the global economy, causing a strict lockdown and a halt to day-to-day activities in every industry. With the limits imposed by the government, the panic scenario has had a negative influence on the industries. The COVID-19 outbreak was one of the most hazardous pandemics that significantly harmed the world economy. When the pandemic first started, several companies were destroyed, while others suffered serious damage. Governments around the world were forced to institute lockdowns, which led to the temporary shutdown of numerous production sites. The tight travel restrictions imposed by nations further impacted the global supply chain.

LATEST TRENDS

Growth of the market in recent years

In terms of revenue, pacemakers led the market for technology used to treat congestive heart failure in 2021. Increased pacemaker usage, pharmaceutical, and medical device R&D are all contributing to the segment's growth. Additionally, because it maintains the heart rhythm painlessly, it is more well-liked by both patients and surgeons. For instance, in June 2021, Medtronic unveiled the tiniest pacemaker ever created to treat heart block.

Since heart pacemakers are delicate medical devices, usage approval is required before they may be sold. In these conditions, a rise in approvals will allow the global market to expand. The criteria for the Food and Drug Administration's approval of devices for cardiac treatment have been lowered. Due to an increase in FDA approvals, businesses are now developing unique products.

Request a Free sample to learn more about this report

ACUTE HEART FAILURE (AHF) THERAPEUTICS MARKET SEGMENTATION

By Type

Based on type the global acute heart failure (AHF) therapeutics market is classified as b-blockers, calcium channel blockers, cardiac glycosides, diuretics, morphine, vasodilators/nitrates, others.

By Application

Based on application the global acute heart failure (AHF) therapeutics market is classified as hospital, clinic, home care.

DRIVING FACTORS

The Utilization as a Catalyst to Boost the Market Growth

The market is expanding as a result of rising cardiovascular operations, changes in contemporary medicine, and technical advancements. The percutaneous circulatory support devices also improve coronary perfusion, decrease ventricular size & filling pressure, maintain perfusion of essential organs, and increase native cardiac output.

Devices including pacemakers, catheters, and automated external defibrillators are permitted in the therapy area. Implantable cardioverter defibrillators are also included. Arrhythmia and atrial fibrillation are on the rise, which is promoting the use of cardiac implantable electronic devices and receiving regulatory approval.

Extensive Application in Laundering Process to Multiply the Production and Market Growth

Due to the approval of new medications, the global market for acute heart failure treatments is anticipated to experience significant expansion. For instance, Novartis' Entresto (TM) (sacubitril/valsartan) tablets were approved by the U.S. Food and Drug Administration (FDA) in July 2015 for the treatment of heart failure with reduced ejection fraction. The use of Entresto is recommended to lower the risk of cardiovascular death and hospitalization for heart failure.

RESTRAINING FACTORS

Several Challenges Associated with the Local Irritation to Restrain the Market

A prevalent disorder with high rates of morbidity, mortality, and expense is acute heart failure. However, there is a paucity of evidence-based information on treating heart failure in the acute environment, and the effectiveness of available individual treatments varies. Additionally, when treating acute heart failure, the healthcare team frequently needs to tailor the patient's care. For instance, dyspnea is the sign of AHF patients most frequently. The fact that other medical disorders, such as pneumonia, exacerbations of chronic obstructive pulmonary disease, pulmonary embolism, acute coronary syndrome, and asthma, are frequently linked to dyspnea makes this symptom non-specific. This is yet another element impeding the market for treatments for acute heart failure (AHF).

• Request a Free sample to learn more about this report

•  

ACUTE HEART FAILURE (AHF) THERAPEUTICS MARKET REGIONAL INSIGHTS

North American Region to Dominate the Market with Extensive Utilization and Multiplying Manufacturers

With the largest revenue share in 2021, North America dominated the global market. The presence of top manufacturers in the United States and the rising frequency of cardiac illnesses in both the United States and Canada are two important factors boosting and supporting market expansion over the predicted timeframe. For instance, according to the CDC's projections, heart disease will account for 1 in every 5 fatalities in the United States in 2020, or about 697,000 deaths. A heart attack happens in the United States every 40 seconds as well. Each year, more than 805,000 Americans have a heart attack. These are a few elements that are encouraging market growth in North America.

KEY INDUSTRY PLAYERS

Financial Players to Contribute Towards Expansion of Market

This market is extremely competitive and consists of various global and regional players. Major players are involved in strategizing various plans such as mergers and acquisitions, partnerships, introduction of new and enhanced products, along with joint ventures. The report is extensive research of a list of market players who contribute towards the expansion of the market. The information is a collusion of latest technological developments, trends, production lines mergers and acquisitions, market study and others. Other factors such as regional wise analysis and segment wise analysis are also considered to understand the market share, product growth, revenue growth and others during the forecasted period.

List of Top Acute Heart Failure (AHF) Therapeutics Companies

• Bayer AG (Germany)
• Bristol-Myers Squibb Company (U.S)
• Cardiorentis AG (U.S)
• CVie Therapeutics Limited (China)
• Cytokinetics, Inc. (U.S)
• Merck & Co. (Germany)
• Novartis AG (Switzerland)
• Orion Corporation (India)
• PhaseBio Pharmaceuticals, Inc(U.S)

REPORT COVERAGE

The SWOT analysis and information on future developments are covered in the study. The research report includes a study of a number of factors that promote market growth. This section also covers the range of numerous market categories and applications that could potentially affect the market in the future. The specifics are based on current trends and historical turning points. The state of the market's components and its potential growth areas over the following years. The paper discusses market segmentation information, including subjective and quantitative research, as well as the impact of financial and strategy opinions. Additionally, the research disseminates data on national and regional assessments that take into account the dominant forces of supply and demand that are influencing market growth. The competitive environment, including market shares of significant competitors, is detailed in the report along with fresh research methodology and player strategies for the anticipated time.